| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2008;118:1567-1576.)
© 2008 American Heart Association, Inc.
Molecular Cardiology |
From the Hubrecht Institute and Interuniversity Cardiology Institute Netherlands, Royal Netherlands Academy of Sciences, Utrecht, Netherlands (P.A.d.C.M., M.B., M.G., M.K., R.J.v.O., L.J.D.W.); Department of Medical Physiology, Division of Heart and Lungs, University Medical Center Utrecht, Utrecht, Netherlands (P.A.d.C.M., M.B., M.G., L.J.D.W.); Heart Failure Research Center, Academic Medical Center, Amsterdam, Netherlands (Y.M.P.); and Department of Pediatrics, Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio (J.D.M.).
Correspondence to Dr Leon J. De Windt, Department of Medical Physiology, University Medical Center Utrecht, Utrecht, Netherlands. E-mail l.j.dewindt{at}umcutrecht.nl
Received January 29, 2008; accepted July 15, 2008.
| Abstract |
|---|
|
|
|---|
Methods and Results— To circumvent the embryonic lethality associated with germline null mutations for Dicer, we triggered conditional Dicer loss through the use of a tamoxifen-inducible Cre recombinase in the postnatal murine myocardium. Targeted Dicer deletion in 3-week-old mice provoked premature death within 1 week accompanied by mild ventricular remodeling and dramatic atrial enlargement. In the adult myocardium, loss of Dicer induced rapid and dramatic biventricular enlargement, accompanied by myocyte hypertrophy, myofiber disarray, ventricular fibrosis, and strong induction of fetal gene transcripts. Comparative miRNA profiling revealed a set of miRNAs that imply causality between miRNA depletion and spontaneous cardiac remodeling.
Conclusions— Overall, these results indicate that modifications in miRNA biogenesis affect both juvenile and adult myocardial morphology and function.
Key Words: Dicer genetics heart failure microRNA
| Introduction |
|---|
|
|
|---|
Editorial p 1524
Clinical Perspective p 1576
Although miRNA studies predominate in the cancer field, miRNAs and their regulatory mechanisms have been highlighted recently in the cardiac field.9–15 Van Rooij and coworkers10 described a number of miRNAs modulated in hypertrophic or failing hearts from mice and humans. Additionally, overexpression of certain miRNAs in cardiomyocytes in vitro induced cardiac hypertrophy, whereas overexpression of the stress-inducible miR-195 in transgenic mice resulted in pathological cardiac remodeling and heart failure.10 The same group described miR-208 as an intronic, cardiac-specific miRNA encoded within the
-myosin heavy chain (
MHC) gene.11 Whereas in the adult heart, absence of miR-208 results in severe blunting of βMHC expression in response to pressure overload or activated calcineurin, expression of βMHC remains unaltered in hearts of newborn miR-208–null mice, demonstrating that this miRNA specifically participates in the mechanism of stress-dependent regulation of βMHC.11 With regard to embryonic heart development, mice lacking miR-1-2 or newborn hearts lacking Dicer have phenotypes ranging from cell cycle dysregulation, hyperproliferation of cardiac myocytes, electric conduction defects, and ventricular-septal malformation,15,16 reflecting the apparent role of single miRNA species to modulate multiple targets. miR-133 and miR-1, which are included in the same bicistronic unit, are specifically expressed in cardiac myocytes and skeletal muscle and play notable regulatory roles in cardiac hypertrophy and skeletal myoblast differentiation, respectively.13,17 Finally, miR-1 is overexpressed in patients with coronary artery disease and, when overexpressed in the rat heart, exacerbates arrhythmogenesis. Conversely, elimination of miR-1 by an antisense inhibitor in infarcted rat hearts relieved arrhythmogenesis.18
Given the importance of the specific miRNAs in heart development and adult cardiac remodeling, it becomes crucial to assess the global requirement of miRNAs in the heart. Dicer, which is critical for processing of pre-miRNAs into their mature form, has been a popular target helping to dissect the significance of miRNAs in mammalian biology. Somatic Dicer loss results in embryonic lethality.19,20 Embryos or newborn mice lacking Dicer in developing heart succumb at embryonic day 12.5 or day 4 after birth with pericardial edema and a very poorly developed ventricular myocardium.15,16 In the present study, we triggered loss of Dicer in the postnatal myocardium through the use of a tamoxifen-inducible Cre recombinase expressed in murine heart cells. Targeted deletion of Dicer in 3-week-old mice resulted in spontaneous cardiac remodeling, impairment of cardiac function, and premature death within 1 week. In the adult myocardium, loss of Dicer induced rapid and dramatic biventricular enlargement, accompanied by hypertrophic growth of cardiomyocytes, myofiber disarray, ventricular fibrosis, strong induction of fetal gene transcripts, and functional defects. Overall, these results indicate that modification of miRNA biogenesis affects both juvenile and adult myocardial morphology and function.
| Methods |
|---|
|
|
|---|
MHC-MerCreMer (
MHC-MCM)22 mice were crossed to generate double-transgenic (
MHC-MCM/DicerF/F) mice. Mice at 3 and 8 weeks of age (
MHC-MCM/DicerF/F and control DicerF/F) were treated with vehicle or tamoxifen (20 mg/kg per day) by daily intraperitoneal injections for consecutive 5 days. Tamoxifen was diluted in 10%/90% vol/vol ethanol/oil to a concentration of 1 mg/100 µL; for the vehicle group, only ethanol/oil solution was injected.
Western Blotting
Mouse cardiac tissue samples were homogenized, proteins were extracted, and Western blotting was performed as described previously.23 Antibodies against Dicer (rabbit polyclonal), GAPDH (mouse monoclonal), and Irx5 (mouse monoclonal) were from Santa Cruz Biotechnology, Inc (Santa Cruz, Calif), and the antibody against Kcnd2 (rabbit polyclonal) was from Chemicon (Temecula, Calif).
Histological Analysis and Immunofluorescence Microscopy
For histological analysis, hearts were arrested in diastole, perfusion-fixed with 4% paraformaldehyde, embedded in paraffin, and sectioned at 5 µm. Paraffin sections were stained with hematoxylin and eosin (H&E) for routine histological analysis, Sirius red for the detection of fibrillar collagen, FITC-labeled wheat-germ agglutinin (WGA) to visualize and quantify the cross-sectional area of the cardiomyocytes, and CD31 (marker of platelet/endothelial cell adhesion molecule-1) to visualize and quantify the number of capillaries per myofiber. Slides were visualized with a Nikon Eclipse E600 microscope or a Zeiss Axiovert 135 (immunofluorescence). Cell surface areas were determined with the use of SPOT imaging software (Diagnostic Instruments).
Transthoracic Echocardiography
Echocardiographic measurements were performed on mice anesthetized with isoflurane as described before,24 1 week and 4 weeks after the start of tamoxifen treatment.
miRNA Profiling
Total RNA was isolated from mouse cardiac tissue samples with the use of TRIzol reagent (Invitrogen, Carlsbad, Calif). The quality of RNA was verified by an Agilent 2100 Bioanalyzer. The expression analysis of 483 miRNA was performed by a miRNA-profiling service (Exiqon, Denmark) with the use of miRCURY LNA arrays. In short, 1 µg of total RNA from tamoxifen-injected
MHC-MCM/DicerF/F mice was labeled with Hy3/Hy5, and the corresponding reference pool sample (vehicle-injected
MHC-MCM/DicerF/F mice) was labeled with Hy5/Hy3 in a dye-swap setup by using an LNA array labeling kit. The Hy3- and Hy5-labeled samples were mixed pairwise and hybridized to the miRCURY LNA array version 8.1, which contains capture probes targeting all miRNAs for all species registered in the miRBASE version 8.1 at the Sanger Institute. The hybridization was performed according to the miRCURY LNA array manual with the use of a Tecan HS4800 hybridization station (Tecan, Austria). After hybridization, the microarray slides were scanned and stored in an ozone-free environment (ozone level <2.0 ppb) to prevent potential bleaching of the fluorescent dyes. The LNA array slides were scanned with the use of the Agilent G2505B Microarray Scanner System (Agilent Technologies, Inc), and image analysis was performed with the use of ImaGene 7.0 software (BioDiscovery, Inc). The raw signal for each probe was obtained by subtracting the maximum of the local background and negative control signals from the foreground signal. The data were preprocessed to remove poor-quality spots, and normalization was used to remove any systematic bias. Quantified signals were normalized with the use of the global Lowess (LOcally WEighted Scatterplot Smoothing) regression algorithm (Exiqon).
Northern Blotting
Three micrograms of total RNA were fractionated on a denaturing 12% polyacrylamide gel containing 8 mol/L urea, transferred to Nytran N membrane (Schleicher & Schuell, Germany) by the capillary method, and fixed by UV cross-linking according to the manufacturers instructions. Membranes were hybridized with specific 5'-digoxigenin–labeled LNA probes for miR-1 or miR-21 (Exiqon). Detection was performed with an antibody to 5'-digoxigenin (Roche).
Quantitative Reverse Transcription Polymerase Chain Reaction
One microgram of total RNA from mouse ventricular tissue was used as template for Superscript reverse transcriptase II (Promega). For real-time reverse transcription polymerase chain reaction (RT-PCR), a Bio-Rad iCycler (Bio-Rad Laboratories, Hercules, Calif) and SYBR Green were used in combination with specific primer sets designed to detect transcripts for nppa, nppb, acta1, myh7, Irx5, kcnd2, angpt1, angpt2, angpt3, vegfa, vegfb, vegfc, vegfd, vegfr1, vegfr2, vegfr3, and hif1a (primer sequences available on request), as described previously in detail.25
Statistical Analysis
The results are presented as mean±SEM values. Statistical analyses were performed with the use of InStat 3.0 software (GraphPad Software Inc) and consisted of ANOVA followed by the Tukey posttest when group differences were detected at the 5% significance level or by the Student t test when 2 experimental groups were compared. Survival was compared by Kaplan–Meier analysis. Differences between parameters at 1 and 4 weeks after cardiac-restricted Dicer deletion were analyzed with SPSS software by applying a 2-way ANOVA for repeated measurements (with Greenhouse-Geisser epsilon correction) with time of measurement as the within factor and treatment as the grouping factor.
The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
| Results |
|---|
|
|
|---|
MHC promoter (
MHC-MCM; Figure 1).22 Dicer mutations will decrease processing of miRNA species in the heart. We therefore analyzed the expression of miRNAs in juvenile hearts after Dicer deletion (Figure 2A). We isolated RNA from tamoxifen- or vehicle-treated 3-week-old
MHC-MCM/DicerF/F mice and performed miRNA profiling on these samples. The samples were Hy3/Hy5-labeled in a dye-swap setup and were mixed pairwise and hybridized to miRCURY LNA arrays, which contained capture probes targeting all miRNAs registered in the miRBASE version 8.1 at the Sanger Institute (345 miRNAs) and probes targeting licensed human sequences not yet annotated in miRBase (138 miRPlus, Exiqon). miRNA profiling identified 161 miRNAs that displayed myocardial expression and a set of 101 miRNAs that were >2-fold differentially expressed between tamoxifen- and vehicle-treated
MHC-MCM/DicerF/F mice (Figure 2A and Tables I and II in the online-only Data Supplement). The microarray results were validated by Northern blot approaches for miR-1 and miR-21 (Figure 2B).
|
|
Tamoxifen treatment of 3-week-old mice induced efficient loss of Dicer protein in the heart as confirmed by Western blot on heart tissue (Figure 2C). On necropsy, tamoxifen-treated
MHC-MCM/DicerF/F mice revealed a slight increase in cardiac size accompanied by grossly enlarged atria filled with atrial thrombi (Figure 2C), which was reflected in a subtle increase in heart weight adjusted for body weight (Figure 2D). We also noted that within 5 days of the start of tamoxifen delivery,
MHC-MCM/DicerF/F mice displayed a weak condition and inactivity compared with tamoxifen-treated DicerF/F or vehicle-treated
MHC-MCM/DicerF/F control mice. Indeed, up to 25% of tamoxifen-treated
MHC-MCM/DicerF/F mice died within 1 week after the start of treatment, and this mortality rate increased up to 75% during the following 2 weeks (P=0.029; Figure 2E).
At 3 weeks of age, deletion of Dicer induced modest left ventricular histopathology. H&E-, Sirius red–, or WGA-stained histological sections displayed a mild degree of inflammatory cell infiltration but no additional myofiber disarray, myocyte hypertrophy, or interstitial fibrosis (Figure 3A). Quantitative real-time PCR on heart tissue from tamoxifen-treated
MHC-MCM/DicerF/F animals compared with tamoxifen- or vehicle-treated DicerF/F control mice revealed a mild but significant upregulation of the "fetal" cardiac genes encoding the natriuretic peptides atrial natriuretic factor (nppa) and brain natriuretic peptide (nppb) and those that encode for sarcomeric proteins
-skeletal actin (acta1) and βMHC (myh7). With a 700% increase, atrial natriuretic factor transcripts were most abundantly enriched in Dicer-deficient hearts, whereas no substantial change was observed in the expression of any of the analyzed marker genes in the control hearts (Figure 3B).
|
Abnormalities in cardiac conduction and repolarization often cause sudden death. Recently, targeted deletion of miR-1 resulted in upregulation of Irx5 and, as a consequence, downregulation of Kcnd2.15 Because we noted that miR-1 was among the most dramatically downregulated microRNAs in juvenile Dicer-depleted mice (Figure 2A and Table II in the online-only Data Supplement), we examined transcript levels for irx5 and kcnd2. Consistent with a previous report,15 we observed a clear upregulation of irx5 transcripts and found that transcripts of the Irx5 target gene kcnd2 were downregulated in the mutant hearts (Figure 3C). A clear increase in the transcriptional repressor Irx5 and a corresponding decrease in Kcnd2 at the protein level were also observed (Figure 3D). These data suggest that dysregulation of the cardiac electric system due to decreased Kcnd2 expression may, at least in part, provoke arrhythmogenesis and the observed sudden death in juvenile Dicer-depleted hearts. In conclusion, cardiac-restricted Dicer deletion in juvenile mice provokes selective reactivation of fetal cardiac genes and a high incidence of spontaneous sudden death, indicating the essential requirement for Dicer in the maturing heart.
Targeted Deletion of Dicer in the Adult Heart Provokes Severe and Spontaneous Hypertrophy
Because deletion of Dicer in juvenile mice resulted in high mortality, we next treated adult
MHC-MCM/DicerF/F and DicerF/F mice with vehicle or tamoxifen at the age of 8 weeks (Figure 1). Next, we analyzed the expression of miRNAs in adult hearts either 1 week or 4 weeks after tamoxifen-mediated Dicer deletion (Figure 1). miRNA profiling identified the same set of 161 miRNAs that displayed myocardial expression and identified 112 miRNAs that were >2-fold differentially expressed between tamoxifen- and vehicle-treated
MHC-MCM/DicerF/F mice at 4 weeks (Tables I and II in the online-only Data Supplement). At 4 weeks after tamoxifen treatment, 42 of 161 myocardial miRNAs remained unaffected, whereas 56 miRNAs were downregulated in expression (Figure 4A and Tables I and II in the online-only Data Supplement). To validate the array results, we confirmed the decrease of miR-1 and increase of miR-21 expression by Northern blot analysis in adult, tamoxifen-treated
MHC-MCM/DicerF/F mice (Figure B).
|
After 1 week, tamoxifen-treated
MHC-MCM/DicerF/F mice exhibited reduced activity in their cages but did not display premature sudden death. In agreement, no effects on survival were observed (data not shown). Low activity can be indicative of heart failure. One week after the tamoxifen regimen, cardiac Dicer protein levels were virtually absent, as confirmed by Western blot (Figure 4C). In addition, hearts from tamoxifen-treated
MHC-MCM/DicerF/F mice displayed doubling in heart weight compared with their control littermates (Figure 4C and 4E). A severe histopathology was evident after staining of histological sections with H&E, Sirius red, WGA, and CD31. Cardiac tissue revealed an intricate phenotype with hypertrophied myofibers, myocyte disarray, strong inflammatory infiltration, and interstitial fibrosis (Figure 4D), hallmark features observed in experimental and clinical heart failure biopsies. CD31 staining demonstrated an aberrant vascularity evidenced by strong vasodilation of preexisting vasculature in tamoxifen-treated
MHC-MCM/DicerF/F mice (Figure 4D), a tendency toward an increase in the relative capillary/myocyte ratio (P=0.077; Figure 4G), and increased expression of several proangiogenic factors and hypoxia-inducible factor-1
(Figure in the online-only Data Supplement). Combined, these results indicate that Dicer depletion in the adult myocardium affects processing of crucial cardiac miRNAs, leading to rapid and spontaneous pathological remodeling.
Targeted Deletion of Dicer in the Adult Heart Decreases Cardiac Function and Induces a Fetal Gene Profile
Cardiac geometry and function were assessed noninvasively by serial echocardiography at 1 and 4 weeks after tamoxifen treatment (Figure 5A, Table). After 1 or 4 weeks, vehicle-treated DicerF/F and MCM-DicerF/F mice demonstrated normal cardiac geometry and function as indicated by fractional shortening (1 week, 40±4% and 49±3%; 4 weeks, 45±3% and 51±3%, respectively; Table, Figure 5B), left ventricular internal dimensions, and left ventricular mass (Figure 5B, 5C, and 5D and Table). As expected, tamoxifen-treated DicerF/F mice showed no alterations in fractional shortening or other parameters Figure 5A through 5D). In contrast, at 1 and 4 weeks, MCM-DicerF/F animals demonstrated a rapid and significant decline in cardiac function, indicated by a 50% decrease in fractional shortening (P<0.05; Table, Figure 5A and 5B). At both time points after tamoxifen treatment, MCM-DicerF/F mice also showed a more pronounced deterioration in cardiac geometry than vehicle-treated MCM-DicerF/F mice, as demonstrated by an increase of 80% to 90% in left ventricular internal diameters (1 week, 1.5±0.3 and 2.7±0.1 mm; 4 weeks, 1.4±0.1 and 2.7±0.1 mm; P<0.05; Table, Figure 5C), indicating a rapid dilation of the left ventricle. Cardiac mass continued to increase progressively by 45% to 60% compared with vehicle-treated MCM-DicerF/F mice (1 week, 48±6 and 71±13 mg; 4 weeks, 60±2 and 95±19 mg, respectively, P<0.05; Table, Figure 5D). These data indicate that Dicer depletion provokes progressive functional and geometric deterioration consistent with a heart failure phenotype.
|
|
Deletion of Dicer in adult mice also induced potent reactivation of embryonic genes such as acta1, nppb, myh7, and nppa by 1300% to 1800% in 8-week-old
MHC-MCM/DicerF/F hearts (Figure 5E). There was no substantial change in the expression of any of these genes in hearts of tamoxifen- or vehicle-treated control genotypes. Conclusively, deletion of Dicer in the adult heart induces rapid and spontaneous cardiac dysfunction with strong induction of fetal hypertrophic marker genes.
| Discussion |
|---|
|
|
|---|
Although several studies have described involvement of specific miRNAs in controlling embryonic development,19,20 myogenesis,17,26,27 cardiogenesis,15,28 and onset of cardiac disease,10,11,13 the overall requirement of miRNAs in the adult heart is less clear. Theoretically, 1 experimental approach to study the contribution of individual miRNA species in the myocardium would be to deplete the myocardium and restore expression of specific miRNAs or miRNA clusters in a myocardial Dicer-null background, as recently described for Dicer mutant zebrafish and miRNA-430.29 We found that deletion of Dicer in the adult mammalian heart resulted in severe myocardial histopathology, suggesting a crucial role for this enzyme in ensuring integrity of the postnatal heart. At early ages (3 weeks), Dicer deletion also provoked sudden death and atrial remodeling, which has previously also been reported for mice lacking miR-1-2 and neonates lacking cardiac Dicer.15,16 Mice lacking miR-1-2 presented evidence of atrial thrombi and sudden death by 2 to 3 months of age caused by cardiac repolarization and conduction defects.15 Indeed, our comparative miRNA profiling analysis at an early age demonstrated strong downregulation of miR-1, upregulation of Irx5 expression, and downregulation of Kcnd2 in Dicer-depleted hearts, suggesting that the phenotypes we observe may be attributable to miR-1 depletion, and implicates Dicer in developmental cardiac maturation and conduction.
To assess the role of Dicer and global requirement for miRNAs in the adult heart, we also deleted Dicer in 8-week-old mice, which provoked a remarkably rapid and spontaneous myocardial growth, accompanied by a severe histopathology. A surprising histological feature was the dramatic change in capillary organization, with strong vasodilation of preexisting vasculature and increased expression of proangiogenic factors. Myocardial vascularization may be affected from adaptive responses to cardiac oxidative stress, which regulates the transcription of an extensive repertoire of genes, including many involved in angiogenesis and vascular remodeling.30,31 Spontaneous adverse cardiac remodeling was further confirmed by functional deficits and acute upregulation of fetal cardiac genes, including those encoded by nppa, nppb, acta1, and myh7. In this respect, it is interesting to note that Thum et al32 recently established that cardiac microRNAs strongly contribute to induction of a fetal gene program in heart failure. The apparent phenotypic difference between postnatal Dicer ablation in juvenile and adult myocardium likely reflects the different maturing states of the postnatal myocardium and could point toward relative differences between overall miRNA biogenesis and biological contribution in the juvenile versus adult myocardium. Clearly, Dicer depletion in the juvenile heart provoked an overall tendency toward arrhythmogenesis and less marked myocyte hypertrophy, whereas in the adult myocardium pronounced myocyte hypertrophy and angiogenic defects were observed. Future studies should seek to provide in-depth understanding of individual, differentially expressed miRNAs in a cardiac disease framework.
Despite efficient, genetic Dicer deletion in the adult heart, we did not observe a preponderance of miRNA repression, which may reflect, in part, the long half-life of certain endogenous miRNAs,33 given that the conditional allele used in this study was recently shown to efficiently reduce miRNA processing in the limb mesoderm.21 In addition, we observed a subset of miRNAs upregulated after tamoxifen treatment. It seems counterintuitive that miRNAs are upregulated in response to Dicer depletion, and we suspect that this is due to the particulars of the genetic models chosen. Indeed, here we used a Cre deleter strain that expresses the transgene only in heart muscle (MHC-MerCreMer), which will only allow for Dicer depletion in the heart muscle when crossbred with DicerF/F mice after tamoxifen treatment. Accordingly, the nonmyocyte fraction remains untouched with our strategy of Dicer depletion. It is likely that miRNAs expressed in the nonmyocyte fraction may respond in a secondary fashion to the observed remodeling processes, resulting in the upregulation of miRNAs in our expression profiling. Finally, we also noted that absolute miRNA expression levels can differ considerably between juvenile and adult hearts, such that for certain miRNAs, absolute expression before Dicer manipulation either increased (eg, mmu-let-7b, mmu-miR-21) or substantially decreased (eg, mmu-miR-145, mmu-miR-451) between the juvenile and adult heart. These 3 factors likely influenced in a combinatorial fashion the observed differential expression of individual miRNAs in our array results (Table I in the online-only Data Supplement). Taken together, our data provide, for the first time, clear evidence for a decisive role for Dicer and miRNA biogenesis in postnatal myocardial integrity. Our profiling lists yielded miRNAs that have not yet been linked to myocardial pathology.
| Acknowledgments |
|---|
Sources of Funding
This work was supported by a 2007 Heart Failure Association Research Fellowship from the European Society of Cardiology (to Dr da Costa Martins); grants 912-04-054 and 912-04-017 and VIDI award 917-863-72 from the Netherlands Organization for Health Research and Development; grant NHS2007B167 from the Netherlands Heart Foundation; and European Union Contract No. LSHM-CT-2005-018833/EUGeneHeart (to Dr De Windt).
Disclosures
None.
| References |
|---|
|
|
|---|
2. Farh KK, Grimson A, Jan C, Lewis BP, Johnston WK, Lim LP, Burge CB, Bartel DP. The widespread impact of mammalian microRNAs on mRNA repression and evolution. Science. 2005; 310: 1817–1821.
3. Pasquinelli AE, Hunter S, Bracht J. MicroRNAs: a developing story. Curr Opin Genet Dev. 2005; 15: 200–205.[CrossRef][Medline] [Order article via Infotrieve]
4. Cullen B. Transcription and processing of human microRNA precursors. Mol Cell. 2004; 16: 861–865.[CrossRef][Medline] [Order article via Infotrieve]
5. Bartel D. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116: 281–297.[CrossRef][Medline] [Order article via Infotrieve]
6. Bentwich IAA, Karov Y, Aharonov R, Gilad S, Barad O, Barzilai A, Einat P, Einav U, Meiri E, Sharon E, Spector Y, Bentwich Z. Identification of hundreds of conserved and nonconserved human microRNAs. Nat Genet. 2005; 37: 766–770.[CrossRef][Medline] [Order article via Infotrieve]
7. Berezikov EGV, van de Belt J, Wienholds E, Plasterk RH, Cuppen E. Phylogenetic shadowing and computational identification of human microRNA genes. Cell. 2005; 120: 21–24.[CrossRef][Medline] [Order article via Infotrieve]
8. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005; 120: 15–20.[CrossRef][Medline] [Order article via Infotrieve]
9. Cheng Y, Ji R, Yue J, Yang J, Liu X, Chen H, Dean DB, Zhang C. MicroRNAs are aberrantly expressed in hypertrophic heart: do they play a role in cardiac hypertrophy? Am J Pathol. 2007; 170: 1831–1840.
10. van Rooij E, Sutherland LB, Liu N, Williams AH, McAnally J, Gerard RD, Richardson JA, Olson EN. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci U S A. 2006; 103: 18255–18260.
11. van Rooij E, Sutherland LB, Qi X, Richardson JA, Hill J, Olson EN. Control of stress-dependent cardiac growth and gene expression by a microRNA. Science. 2007; 316: 575–579.
12. Sayed DHC, Chen IY, Lypowy J, Abdellatif M. MicroRNAs play an essential role in the development of cardiac hypertrophy. Circ Res. 2007; 100: 416–424.
13. Care A, Catalucci D, Felicetti F, Bonci D, Addario A, Gallo P, Bang ML, Segnalini P, Gu Y, Dalton ND, Elia L, Latronico MV, Hoydal M, Autore C, Russo MA, Dorn GW II, Ellingsen O, Ruiz-Lozano P, Peterson KL, Croce CM, Peschle C, Condorelli G. MicroRNA-133 controls cardiac hypertrophy. Nat Med. 2007; 13: 613–618.[CrossRef][Medline] [Order article via Infotrieve]
14. Tatsuguchi M, Seok HY, Callis TE, Thomson JM, Chen JF, Newman M, Rojas M, Hammond SM, Wang DZ. Expression of microRNAs is dynamically regulated during cardiomyocyte hypertrophy. J Mol Cell Cardiol. 2007; 42: 1137–1141.[CrossRef][Medline] [Order article via Infotrieve]
15. Zhao Y, Ransom JF, Li A, Vedantham V, von Drehle M, Muth AN, Tsuchihashi T, McManus MT, Schwartz RJ, Srivastava D. Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1–2. Cell. 2007; 129: 303–317.[CrossRef][Medline] [Order article via Infotrieve]
16. Chen JF, Murchison EP, Tang R, Callis TE, Tatsuguchi M, Deng Z, Rojas M, Hammond SM, Schneider MD, Selzman CH, Meissner G, Patterson C, Hannon GJ, Wang DZ. Targeted deletion of Dicer in the heart leads to dilated cardiomyopathy and heart failure. Proc Natl Acad Sci U S A. 2008; 105: 2111–2116.
17. Chen JF, Mandel EM, Thomson JM, Wu Q, Callis TE, Hammond SM, Conlon FL, Wang DZ. The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat Genet. 2006; 38: 228–233.[CrossRef][Medline] [Order article via Infotrieve]
18. Yang B, Lin H, Xiao J, Lu Y, Luo X, Li B, Zhang Y, Xu C, Bai Y, Wang H, Chen G, Wang Z. The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2. Nat Med. 2007; 13: 486–491.[CrossRef][Medline] [Order article via Infotrieve]
19. Bernstein E, Kim SY, Carmell MA, Murchison EP, Alcorn H, Li MZ, Mills AA, Elledge SJ, Anderson KV, Hannon GJ. Dicer is essential for mouse development. Nat Genet. 2003; 35: 215–217.[CrossRef][Medline] [Order article via Infotrieve]
20. Yang WJ, Yang DD, Na S, Sandusky GE, Zhang Q, Zhao G. Dicer is required for embryonic angiogenesis during mouse development. J Biol Chem. 2005; 280: 9330–9335.
21. Harfe BD, McManus MT, Mansfield JH, Hornstein E, Tabin CJ. The RNaseIII enzyme Dicer is required for morphogenesis but not patterning of the vertebrate limb. Proc Natl Acad Sci U S A. 2005; 102: 10898–10903.
22. Sohal DS, Nghiem M, Crackower MA, Witt SA, Kimball TR, Tymitz KM, Penninger JM, Molkentin JD. Temporally regulated and tissue-specific gene manipulations in the adult and embryonic heart using a tamoxifen-inducible Cre protein. Circ Res. 2001; 89: 20–25.
23. De Windt LJ, Lim HW, Haq S, Force T, Molkentin JD. Calcineurin promotes protein kinase C and c-Jun NH2-terminal kinase activation in the heart: cross-talk between cardiac hypertrophic signaling pathways. J Biol Chem. 2000; 275: 13571–13579.
24. van Rooij E, Doevendans PA, Crijns HJ, Heeneman S, Lips DJ, van Bilsen M, Williams RS, Olson EN, Bassel-Duby R, Rothermel BA, De Windt LJ. MCIP1 overexpression suppresses left ventricular remodeling and sustains cardiac function after myocardial infarction. Circ Res. 2004; 94: e18–e26.[CrossRef][Medline] [Order article via Infotrieve]
25. van Oort RJ, van Rooij E, Bourajjaj M, Schimmel J, Jansen MA, van der Nagel R, Doevendans PA, Schneider MD, van Echteld CJ, De Windt LJ. MEF2 activates a genetic program promoting chamber dilation and contractile dysfunction in calcineurin-induced heart failure. Circulation. 2006; 114: 298–308.
26. Sokol NS, Ambros V. Mesodermally expressed Drosophila microRNA-1 is regulated by Twist and is required in muscles during larval growth. Genes Dev. 2005; 19: 2343–2354.
27. Kim HK, Lee YS, Sivaprasad U, Malhotra A, Dutta A. Muscle-specific microRNA miR-206 promotes muscle differentiation. J Cell Biol. 2006; 174: 677–687.
28. Zhao Y, Samal E, Srivastava D. Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis. Nature. 2005; 436: 214–220.[CrossRef][Medline] [Order article via Infotrieve]
29. Giraldez AJ, Cinalli RM, Glasner ME, Enright AJ, Thomson JM, Baskerville S, Hammond SM, Bartel DP, Schier AF. MicroRNAs regulate brain morphogenesis in zebrafish. Science. 2005; 308: 833–838.
30. Ryan HE, Lo J, Johnson RS. HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J. 1998; 17: 3005–3015.[CrossRef][Medline] [Order article via Infotrieve]
31. Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin M, Neeman M, Bono F, Abramovitch R, Maxwell P, Koch CJ, Ratcliffe P, Moons L, Jain RK, Collen D, Keshert E. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature. 1998; 394: 485–490.[CrossRef][Medline] [Order article via Infotrieve]
32. Thum T, Galuppo P, Wolf C, Fiedler J, Kneitz S, van Laake LW, Doevendans PA, Mummery CL, Borlak J, Haverich A, Gross C, Engelhardt S, Ertl G, Bauersachs J. MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure. Circulation. 2007; 116: 258–267.
33. Kim VN. MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol. 2005; 6: 376–385.[CrossRef][Medline] [Order article via Infotrieve]
| Footnotes |
|---|
Related Article:
Circulation 2008 118: 1519-1520.
This article has been cited by other articles:
![]() |
P. K. Rao, Y. Toyama, H. R. Chiang, S. Gupta, M. Bauer, R. Medvid, F. Reinhardt, R. Liao, M. Krieger, R. Jaenisch, et al. Loss of Cardiac microRNA-Mediated Regulation Leads to Dilated Cardiomyopathy and Heart Failure Circ. Res., September 11, 2009; 105(6): 585 - 594. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Catalucci, P. Gallo, and G. Condorelli MicroRNAs in Cardiovascular Biology and Heart Disease Circ Cardiovasc Genet, August 1, 2009; 2(4): 402 - 408. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Gladka, H. el Azzouzi, L. J. De Windt, and P. A. da Costa Martins Aquaporin 7: the glycerol aquaeductus in the heart Cardiovasc Res, July 1, 2009; 83(1): 3 - 4. [Full Text] [PDF] |
||||
![]() |
A. Haghikia and D. Hilfiker-Kleiner MiRNA-21: a key to controlling the cardiac fibroblast compartment? Cardiovasc Res, April 1, 2009; 82(1): 1 - 3. [Full Text] [PDF] |
||||
![]() |
K. R. Cordes and D. Srivastava MicroRNA Regulation of Cardiovascular Development Circ. Res., March 27, 2009; 104(6): 724 - 732. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Suarez and W. C. Sessa MicroRNAs As Novel Regulators of Angiogenesis Circ. Res., February 27, 2009; 104(4): 442 - 454. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Thum Cardiac Dissonance Without Conductors: How Dicer Depletion Provokes Chaos in the Heart Circulation, October 7, 2008; 118(15): 1524 - 1527. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2008 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |